334 related articles for article (PubMed ID: 30102854)
21. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
Raj U; Kumar H; Varadwaj PK
J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
[TBL] [Abstract][Full Text] [Related]
22. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
Tumdam R; Kumar A; Subbarao N; Balaji BS
SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
[TBL] [Abstract][Full Text] [Related]
23. Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site.
Liu Z; Li Y; Chen H; Lai HT; Wang P; Wu SY; Wold EA; Leonard PG; Joseph S; Hu H; Chiang CM; Brasier AR; Tian B; Zhou J
J Med Chem; 2022 Feb; 65(3):2388-2408. PubMed ID: 34982556
[TBL] [Abstract][Full Text] [Related]
24. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
Ciceri P; Müller S; O'Mahony A; Fedorov O; Filippakopoulos P; Hunt JP; Lasater EA; Pallares G; Picaud S; Wells C; Martin S; Wodicka LM; Shah NP; Treiber DK; Knapp S
Nat Chem Biol; 2014 Apr; 10(4):305-12. PubMed ID: 24584101
[TBL] [Abstract][Full Text] [Related]
25. Naphthyridines as novel BET family bromodomain inhibitors.
Mirguet O; Lamotte Y; Chung CW; Bamborough P; Delannée D; Bouillot A; Gellibert F; Krysa G; Lewis A; Witherington J; Huet P; Dudit Y; Trottet L; Nicodeme E
ChemMedChem; 2014 Mar; 9(3):580-9. PubMed ID: 24000170
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site.
Chen H; Tucker J; Wang X; Gavine PR; Phillips C; Augustin MA; Schreiner P; Steinbacher S; Preston M; Ogg D
Acta Crystallogr D Struct Biol; 2016 May; 72(Pt 5):682-93. PubMed ID: 27139631
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
29. Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.
Allen BK; Mehta S; Ember SW; Schonbrunn E; Ayad N; Schürer SC
Sci Rep; 2015 Nov; 5():16924. PubMed ID: 26596901
[TBL] [Abstract][Full Text] [Related]
30. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes.
Baud MGJ; Lin-Shiao E; Cardote T; Tallant C; Pschibul A; Chan KH; Zengerle M; Garcia JR; Kwan TT; Ferguson FM; Ciulli A
Science; 2014 Oct; 346(6209):638-641. PubMed ID: 25323695
[TBL] [Abstract][Full Text] [Related]
31. In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4.
Rodríguez Y; Gerona-Navarro G; Osman R; Zhou MM
Proteins; 2020 Mar; 88(3):414-430. PubMed ID: 31587361
[TBL] [Abstract][Full Text] [Related]
32. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
[TBL] [Abstract][Full Text] [Related]
34. Design and Synthesis of Pyrrolo[2,3-
Williamson DS; Smith GP; Mikkelsen GK; Jensen T; Acheson-Dossang P; Badolo L; Bedford ST; Chell V; Chen IJ; Dokurno P; Hentzer M; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Wang Y; Christensen KV
J Med Chem; 2021 Jul; 64(14):10312-10332. PubMed ID: 34184879
[TBL] [Abstract][Full Text] [Related]
35. Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.
Cui H; Divakaran A; Pandey AK; Johnson JA; Zahid H; Hoell ZJ; Ellingson MO; Shi K; Aihara H; Harki DA; Pomerantz WCK
Angew Chem Int Ed Engl; 2021 Jan; 60(3):1220-1226. PubMed ID: 32975004
[TBL] [Abstract][Full Text] [Related]
36. Selective inhibition of BET bromodomains.
Filippakopoulos P; Qi J; Picaud S; Shen Y; Smith WB; Fedorov O; Morse EM; Keates T; Hickman TT; Felletar I; Philpott M; Munro S; McKeown MR; Wang Y; Christie AL; West N; Cameron MJ; Schwartz B; Heightman TD; La Thangue N; French CA; Wiest O; Kung AL; Knapp S; Bradner JE
Nature; 2010 Dec; 468(7327):1067-73. PubMed ID: 20871596
[TBL] [Abstract][Full Text] [Related]
37. Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains.
Zhang G; Plotnikov AN; Rusinova E; Shen T; Morohashi K; Joshua J; Zeng L; Mujtaba S; Ohlmeyer M; Zhou MM
J Med Chem; 2013 Nov; 56(22):9251-64. PubMed ID: 24144283
[TBL] [Abstract][Full Text] [Related]
38. Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold.
Remillard D; Buckley DL; Seo HS; Ferguson FM; Dhe-Paganon S; Bradner JE; Gray NS
ACS Med Chem Lett; 2019 Oct; 10(10):1443-1449. PubMed ID: 31620231
[TBL] [Abstract][Full Text] [Related]
39. Targeting BET bromodomains for cancer treatment.
Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
[TBL] [Abstract][Full Text] [Related]
40. Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.
Nguyen D; Lemos C; Wortmann L; Eis K; Holton SJ; Boemer U; Moosmayer D; Eberspaecher U; Weiske J; Lechner C; Prechtl S; Suelzle D; Siegel F; Prinz F; Lesche R; Nicke B; Nowak-Reppel K; Himmel H; Mumberg D; von Nussbaum F; Nising CF; Bauser M; Haegebarth A
J Med Chem; 2019 Jan; 62(2):928-940. PubMed ID: 30563338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
